Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | CCKAR | P32238 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinolazepam SCHEMBL4457397 | 1.00 | OPRK1 (0.53) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| Cinolazepam SCHEMBL30338063 | 1.00 | OPRK1 (0.53) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| Cinolazepam SCHEMBL28142897 | 0.96 | OPRK1 (0.50) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| SCHEMBL7330064 | 0.90 | OPRK1 (0.67) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| Doxefazepam SCHEMBL554909 | 0.88 | OPRK1 (0.57) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| Doxefazepam SCHEMBL31128398 | 0.88 | OPRK1 (0.57) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| SCHEMBL7320833 | 0.87 | OPRK1 (0.66) | OPRK1CHRM2ADRA2APDE4DKCNH2 | |
| SCHEMBL7323323 | 0.85 | CCKBR (0.49) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| SCHEMBL7332842 | 0.85 | CCKBR (0.47) | OPRK1CHRM2ADRA2APDE4DCYP3A4 | |
| Cinolazepam SCHEMBL28086502 | 0.84 | OPRK1 (0.47) | OPRK1CHRM2ADRA2APDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210186927-A1 | COMBINATION PRODUCT FOR THE INDUCTION AND/OR MAINTENANCE OF GENERAL ANESTHESIA | TERRAN BIOSCIENCES, INC. | 2021-06-24 | — | — | US | claimed |
| EP-3773723-A1 | COMBINATION PRODUCT FOR THE INDUCTION AND/OR MAINTENANCE OF GENERAL ANESTHESIA | BlumenTech S.L. (ES) | 2021-02-17 | — | — | EP | claimed |
| US-20200345723-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL INC (US) | 2020-11-05 | — | — | US | claimed |
| US-20200345722-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | COLLEGIUM PHARMACEUTICAL INC (US) | 2020-11-05 | — | — | US | claimed |
| US-20200316087-A1 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2020-10-08 | — | — | US | claimed |
| US-20200187851-A1 | PERIODONTAL DISEASE STRATIFICATION AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2020-06-18 | — | — | US | claimed |
| US-20200093819-A1 | ABUSE-DETERRENT DRUG FORMULATIONS | COLLEGIUM PHARMACEUTICAL, INC. | 2020-03-26 | — | — | US | claimed |
| US-20200093820-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2020-03-26 | — | — | US | claimed |
| WO-2019197594-A1 | COMBINATION PRODUCT FOR THE INDUCTION AND/OR MAINTENANCE OF GENERAL ANESTHESIA | BLUMENTECH, S.L. (ES) | 2019-10-17 | — | — | WO | claimed |
| WO-2019070910-A1 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN | UWM RESEARCH FOUNDATION, INC. (US) | 2019-04-11 | — | — | WO | claimed |
| US-20040058946-A1 | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals | COLLEGIUM PHARMACEUTICAL, INC. | 2004-03-25 | — | — | US | claimed |
| US-20040052731-A1 | Abuse-deterrent pharmaceutical compositions of opiods and other drugs | COLLEGIUM PHARMACEUTICALS, INC. | 2004-03-18 | — | — | US | claimed |
| WO-2004004693-A1 | ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS | COLLGEGIUM PHARMACEUTICAL (US) | 2004-01-15 | — | — | WO | claimed |
| WO-2003004015-A1 | OIL-IN-WATER EMULSIONS COMPRISING A BENZODIAZEPINE DRUG | WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINICAL RESEARCH CENTRE LIMITED (GB) | 2003-01-16 | — | — | WO | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| US-20020143188-A1 | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use | GARVEY DAVID S (US) | 2002-10-03 | — | — | US | claimed |
| EP-1140011-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION DESIGNED TO PREVENT MISUSE AT THE EXPENSE OF A THIRD PARTY | Sanofi-Aventis (FR) | 2001-10-10 | — | — | EP | claimed |
| WO-2000067754-A1 | NITROSATED AND NITROSYLATED POTASSIUM CHANNEL ACTIVATORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-11-16 | — | — | WO | claimed |
| WO-2000038649-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION DESIGNED TO PREVENT MISUSE AT THE EXPENSE OF A THIRD PARTY | SANOFI-SYNTHELABO (FR) | 2000-07-06 | — | — | WO | claimed |
| US-4388313-A | Novel 3-hydroxy-1,4-benzodiazepine-2-ones and process for the preparation thereof | GEROT-PHARMAZEUTIKA GESELLSCHAFT M.B.H. (AT) | 1983-06-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058946-A1 | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals | OPRK1, OPRM1, OPRL1 | OPRK1 1/4885CHRM2 949/4885ADRA2A 234/4885 |
| US-20210186927-A1 | COMBINATION PRODUCT FOR THE INDUCTION AND/OR MAINTENANCE OF GENERAL ANESTHESIA | OPRK1, OPRD1, GABRD | OPRK1 1/4885CHRM2 237/4885ADRA2A 86/4885 |
| US-20020143188-A1 | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use | KCNN3, KCNN1, KCNN2 | OPRK1 834/4885CHRM2 364/4885ADRA2A 377/4885 |
| US-20200316087-A1 | NOVEL COMBINATION THERAPY FOR ANXIETY DISORDERS, EPILEPSY, AND PAIN | GABRB2, GABRB1, GABRB3 | OPRK1 115/4885CHRM2 1027/4885ADRA2A 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.